ECT2 and prostate carcinoma: Similarly, the top gene set whose GSAS was different between resistant and sensitive metastatic prostate samples to abiraterone treatment was driven by KNSTRN, ECT2 and RCC2 genes, three genes previously associated with prostate cancer progression (69–71).